Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 and Chemotherapy in Transformed Small Cell Lung Cancer
NCT07476287Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of PF-08634404 in small cell lung cancer (SCLC), sponsored by Pfizer. Started Jul 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07476287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476287.